Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD provides update on veterinary medicines containing Diethanolamine
Stocks of authorised flunixin injections for non-food horses only are now available on the UK market.
Flunixin provided under ‘caution in use’ letter must cease immediately 

The Veterinary Medicines Directorate (VMD) has provided an update on medicines containing Diethanolamine (DEA), which were suspended in 2018 over concerns of a risk to humans from consuming food from animals treated with the products.

In a previous announcement, the VMD permitted supply of flunixin products (which contain DEA) for use in non-food producing horses, provided the supply was accompanied by a ‘Caution in Use’ letter for the veterinary surgeon. This was to address the potential lack of availability of flunixin for intravenous use in non-food horses

In its latest update, the VMD writes that stocks of authorised flunixin injections for non-food horses only are now available on the UK market and authorised product for food producing species (reformulated to remove diethanolamine) will shortly be available.

As such, the supply of any existing stock accompanied by a ‘Caution in Use’ letter, must now cease immediately.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.